16:51:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-28 Kvartalsrapport 2024-Q2
2024-05-27 Ordinarie utdelning PCIB 0.00 NOK
2024-05-24 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-11-22 15-10 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning PCIB 0.00 NOK
2023-05-25 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning PCIB 0.00 NOK
2022-05-25 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning PCIB 0.00 NOK
2021-05-28 Årsstämma 2021
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning PCIB 0.00 NOK
2020-05-27 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning PCIB 0.00 NOK
2019-05-29 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning PCIB 0.00 NOK
2018-05-29 Årsstämma 2018
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-19 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-05-30 Ordinarie utdelning PCIB 0.00 NOK
2017-05-29 Årsstämma 2017
2017-05-16 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-12-08 Extra Bolagsstämma 2016
2016-11-22 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-05-20 Ordinarie utdelning PCIB 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-03 Kvartalsrapport 2016-Q1
2016-02-09 Bokslutskommuniké 2015
2015-11-17 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning PCIB 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-12 Kvartalsrapport 2015-Q1
2015-02-24 Bokslutskommuniké 2014
2014-11-18 Kvartalsrapport 2014-Q3
2014-08-19 Kvartalsrapport 2014-Q2
2014-05-14 Ordinarie utdelning
2014-05-13 Kvartalsrapport 2014-Q1
2014-05-13 Årsstämma 2014
2014-02-25 Bokslutskommuniké 2013
2013-10-29 Kvartalsrapport 2013-Q3
2013-08-20 Kvartalsrapport 2013-Q2
2013-05-07 Ordinarie utdelning
2013-05-06 Årsstämma 2013
2013-04-30 Kvartalsrapport 2013-Q1
2013-03-21 Bokslutskommuniké 2012
2012-10-30 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-08 Kvartalsrapport 2012-Q1
2012-04-26 Ordinarie utdelning
2012-04-25 Årsstämma 2012
2012-02-07 Bokslutskommuniké 2011
2011-11-01 Kvartalsrapport 2011-Q3
2011-08-23 Kvartalsrapport 2011-Q2
2011-05-10 Kvartalsrapport 2011-Q1
2011-04-14 Ordinarie utdelning
2010-10-25 Kvartalsrapport 2010-Q3
2010-08-23 Kvartalsrapport 2010-Q2
2010-05-19 Ordinarie utdelning
2010-05-18 Årsstämma 2010
2010-04-26 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-10-26 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-29 Kvartalsrapport 2009-Q1

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
PCI Biotech Holding är en biofarmaceutiskt koncern, där största delen av verksamheten bedrivs inom dotterbolaget PCI Biotech. Koncernen bedriver idag verksamhet inom utveckling av terapeutiska produkter baserat på den egenutvecklade PCI tekniken. Lösningarna är avsedda att användas vid behandling utav cancerpatienter. PCI Biotech grundades ursprungligen 2000 som ett dotterbolag till Photocure och har idag sitt huvudkontor i Oslo, Norge.
2022-11-25 18:08:44

Oslo, 25 November 2022 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.        

In accordance with the authorisation granted by the Annual General Meeting 25 May 2022 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 570,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech’s choice), at a strike price of NOK 1.90, equal to the volume weighted average share price (VWAP) for the last 5 days of trade prior to the grant date. However, the current nominal value of the share is NOK 3.00 and the strike price cannot be lower than the nominal value of the share at the future exercise date(s). The share options are granted without consideration and are subject to service based vesting conditions, and the share options will vest equally over a three-year vesting term. The share options are lapsing in Q3 2027. Further details about the share option program are described in PCI Biotech’s remuneration policy.

According to the remuneration policy the BoD will at allotment of share options seek to allot a number of share options with a total fair value, calculated according to the Black-Scholes model, that is partly linked to the annual base salary for each individual. Other elements that will be assessed in the allotment are the balance between total short- and longterm performance based rewards, current value of share options held, overall performance, work responsibility, importance of retention and position.

The number of share options granted is based on these guidelines and in addition, the share options are granted with a value cap of 20 times the strike price of NOK 1.90. If this value cap threshold is met all share options will vest immediately and be available for exercise.

To ensure long-term ownership by executive management, shares obtained by exercise of share options shall be held for at least one year, except shares to be sold immediately to cover transaction costs and tax under a so-called cash less exercise. Through the long-term incentive program the board expects members of the executive team to build up and maintain share ownership with a market value equal to at least one-year gross base salary, before any shares may be sold. No lock-up elements are applicable for other employees.

Of the 570,000 share options, 360,000 share options were allotted to the following primary insiders:

220,000 share options were allotted to Ronny Skuggedal, CEO. After the allotment, Ronny Skuggedal holds a total portfolio of 360,000 unexercised share options and 55,000 shares.

120,000 share options were allotted to Anders Høgset, CSO. After the allotment, Anders Høgset holds a total portfolio of 250,000 unexercised share options and 64,800 shares.

20,000 share options were allotted to Kristin Eivindvik, CDO. After the allotment, Kristin Eivindvik holds a total portfolio of 110,000 unexercised share options and 25,200 shares.

Primary insider notifications pursuant to the market abuse regulation article 19 are attached.

The current authorisation, as of 25 May 2022, allows for a total of 2,790,000 share options, of which 1,000,000 now have been granted by the Board of Directors.

For more information, please contact:        
Ronny Skuggedal, CEO, rs(a)pcibiotech.no, Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and to section 5-12 of the Norwegian Securities Trading Act.